225 related articles for article (PubMed ID: 15795263)
21. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
22. A template-assembled model of the N-peptide helix bundle from HIV-1 Gp-41 with high affinity for C-peptide.
Xu W; Taylor JW
Chem Biol Drug Des; 2007 Oct; 70(4):319-28. PubMed ID: 17937777
[TBL] [Abstract][Full Text] [Related]
23. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
[TBL] [Abstract][Full Text] [Related]
24. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
Zhuang M; Wang W; De Feo CJ; Vassell R; Weiss CD
J Biol Chem; 2012 Mar; 287(11):8297-309. PubMed ID: 22235115
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of the entry of HIV into host cells.
Meanwell NA; Kadow JF
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):451-61. PubMed ID: 12951808
[TBL] [Abstract][Full Text] [Related]
26. The role of the N-terminal heptad repeat of HIV-1 in the actual lipid mixing step as revealed by its substitution with distant coiled coils.
Wexler-Cohen Y; Sackett K; Shai Y
Biochemistry; 2005 Apr; 44(15):5853-61. PubMed ID: 15823044
[TBL] [Abstract][Full Text] [Related]
27. A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41.
Joshi SB; Dutch RE; Lamb RA
Virology; 1998 Aug; 248(1):20-34. PubMed ID: 9705252
[TBL] [Abstract][Full Text] [Related]
28. Development of a FRET assay for monitoring of HIV gp41 core disruption.
Xu Y; Hixon MS; Dawson PE; Janda KD
J Org Chem; 2007 Aug; 72(18):6700-7. PubMed ID: 17685571
[TBL] [Abstract][Full Text] [Related]
29. Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.
De Feo CJ; Wang W; Hsieh ML; Zhuang M; Vassell R; Weiss CD
Retrovirology; 2014 Oct; 11():86. PubMed ID: 25274545
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
31. Direct evidence that the N-terminal heptad repeat of Sendai virus fusion protein participates in membrane fusion.
Ghosh JK; Shai Y
J Mol Biol; 1999 Sep; 292(3):531-46. PubMed ID: 10497019
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates.
Santos-Costa Q; Parreira R; Moniz-Pereira J; Azevedo-Pereira JM
J Med Virol; 2009 Nov; 81(11):1869-81. PubMed ID: 19774680
[TBL] [Abstract][Full Text] [Related]
33. Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection.
Liu D; Wang H; Yamamoto M; Song J; Zhang R; Du Q; Kawaguchi Y; Inoue JI; Matsuda Z
Retrovirology; 2018 Apr; 15(1):27. PubMed ID: 29609648
[TBL] [Abstract][Full Text] [Related]
34. Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.
Salzwedel K; Berger EA
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12794-9. PubMed ID: 11050186
[TBL] [Abstract][Full Text] [Related]
35. Atomic structure of the ectodomain from HIV-1 gp41.
Weissenhorn W; Dessen A; Harrison SC; Skehel JJ; Wiley DC
Nature; 1997 May; 387(6631):426-30. PubMed ID: 9163431
[TBL] [Abstract][Full Text] [Related]
36. X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution.
Watabe T; Terakawa Y; Watanabe K; Ohno H; Nakano H; Nakatsu T; Kato H; Izumi K; Kodama E; Matsuoka M; Kitaura K; Oishi S; Fujii N
J Mol Biol; 2009 Sep; 392(3):657-65. PubMed ID: 19616557
[TBL] [Abstract][Full Text] [Related]
37. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
[TBL] [Abstract][Full Text] [Related]
38. Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope.
Sabatier JM; Mabrouk K; Moulard M; Rochat H; Van Rietschoten J; Fenouillet E
Virology; 1996 Sep; 223(2):406-8. PubMed ID: 8806580
[TBL] [Abstract][Full Text] [Related]
39. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
Korazim O; Sackett K; Shai Y
J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
[TBL] [Abstract][Full Text] [Related]
40. Trimerization specificity in HIV-1 gp41: analysis with a GCN4 leucine zipper model.
Shu W; Ji H; Lu M
Biochemistry; 1999 Apr; 38(17):5378-85. PubMed ID: 10220324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
